Navigation Links
Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa
Date:11/8/2010

Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant... -- ABBOTT PARK, Ill., Nov. 8, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Infection Control, Medical Pharmaceuticals, Pharmaceuticals, Joint Ventures, Children-related News, Domestic Policy, Corporate Social Responsibility Click to view news release full screen  

Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa

 

ABBOTT PARK, Ill., Nov. 8, 2010 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and the Clinton Health Access Initiative (CHAI) have joined forces to provide HIV testing to infants in all countries working in partnership with the CHAI.  A key focus of this cooperation will be sub-Saharan Africa, which the World Health Organization estimates to account for 90 percent of global HIV infections in children.

Under terms of the agreement, Abbott will supply its RealTime HIV-1 Qualitative test kits to healthcare facilities.  The test is currently available for research use only and is expected to be CE marked (Conformite Europeene) by January 2011.  Abbott will also offer the capability to collect and process samples using dried blood spots (DBS).  The use of DBS for specimen collection eliminates the need for refrigeration of specimens.

In addition to the supply of HIV tests and DBS sample collection for research use, Abbott is collaborating with CHAI to develop a "turn-key" laboratory solution, including training protocols on instruments that will be used to establish fully functioning molecular diagnostic laboratories in regions where such facilities do not currently exist.

"We're pleased to be collaborating with the CHAI in its proactive outreach effort to test infants in developing nations for HIV," said Stafford O'Kelly, head of Abbott's molecular diagnostics business.  "Accurate and accessible HIV testing, particularly for diagnosis of HIV/AIDS in infants less than 18 months of age, is essential for optimal management and treatment of the disease."

About Abbott Molecular Abbott Molecular, abbottmolecular.com, is an emerging leader in molecular diagnostics - the analysis of DNA, RNA, and proteins at the molecular level.  Abbott Molecular's instruments and assays are used for early detection and diagnosis of disease, to influence the selection of appropriate therapies and as an aid in monitoring disease progression.

About Abbott Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
2. Abbott Again Recognized for Environmental Initiatives in Illinois
3. Abbott Statement: Abbott Provides Support for Cholera Relief Efforts in Haiti
4. Abbott to Voluntarily Withdraw Meridia® (Sibutramine) in the U.S.
5. Abbott Laboratories Agrees to Withdraw Its Obesity Drug Meridia
6. Abbott Named One of the Top Employers in the Biotech and Pharmaceutical Industry by Science Magazine
7. Abbott Receives FDA Market Clearance for Next-Generation Contact Lens Disinfecting Solution
8. Abbotts XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
9. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
10. Abbotts Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results
11. The Deal Names Abbott Top Dealmaker for Third Consecutive Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Israel , May 4, 2016 ... today that BiondVax,s CEO, Dr. Ron Babecoff , will ... New York City . On Thursday, ... Pioneers 2016, a conference presented by Joseph Gunner ... The BiondVax presentation that Dr. Babecoff will be ...
(Date:5/4/2016)... D.C. , May 4, 2016 ... member companies concluded a series of free workshops ... in global requirements for Good Distribution ... of quality assurance which ensures that products are consistently stored, ... the marketing authorization (MA) or product specification. Only a ...
(Date:5/4/2016)... 2016 Research and ... Acute Ischemic Stroke Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Stroke Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Ischemic Stroke epidemiology, Acute ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... NCPDP ... opened on Tuesday with Frank Luntz, sharing a dynamic, bi-partisan environmental scan of ... deep dive on NCPDP’s model solution to help stem the tide of the ...
(Date:5/4/2016)... ... May 04, 2016 , ... The RIDER Institute announces ... of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against all 18 viruses ... 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, we are raising ...
(Date:5/4/2016)... ... May 04, 2016 , ... a2z, ... Society™ and Canadian Association for Enterostomal Therapy (CAET) will be utilizing powerful ... planning tools to attendees and exhibitors for the 2016 WOCN Society & CAET ...
(Date:5/4/2016)... , ... May 04, 2016 , ... May kicked off ... people across the United States. Dermatologist Dr. Ellen Turner is encouraging her patients, as ... advice and focus on skin safety and health now and in the future. , ...
(Date:5/4/2016)... MO (PRWEB) , ... May 04, 2016 , ... Recognizing ... newly launched health brand, Verywell, have tapped David Katz, MD, MPH, president ... , “Our shared devotion to lifestyle medicine is especially gratifying,” said Katz. “There ...
Breaking Medicine News(10 mins):